Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The first “p” value corresponds to the comparison between the three groups and the second value corresponds to the comparison between ADPKD and patients with CKD from other etiologies (CKD stages 3, 4 and 5 not on dialysis)Controlsn = 498 (28.4%)ADPKDn = 132 (7.5%)CKDoen = 1121 (64.1%)PComparison three groupsPADPKD vs CKDoeAge (years)53.69 ± 116353.60 ± 11.0959.56 ± 12.22< 0.001< 0.001Male gender262 (52.5%)67 (50.8%)700 (62.1%)< 0.0010.012BMI (Kg/m2)27.82 ± 4.4027.55 ± 4.6528.56 ± 4.940.0030.02Obesity (BMI > 30 Kg/m2)131 (26.3%)35 (26.5%)251 (34.9%)0.0100.03Active smoking100 (20.0%)34 (25.7%)212 (18.7%)NSNSHypertension163 (32.7%)123 (93.2%)1017 (90.2%)< 0.001NSDyslipidemia157 (31.5%)82 (62.1%)762 (67.6%)< 0.001NSCKD stage 30 (0.0%)57 (43.2%)635 (56.3%)< 0.0010.004CKD stages 4 to 50 (0.0%)75 (56.8%)493 (43.7%)< 0.0010.004Creatinine (mg/dL)0.84 ± 0.153.00 ± 1.772.37 ± 1.18< 0.001< 0.001eGFR (mL/min/1.73m2)91.82 ± 16.9427.50 ± 14.0933.46 ± 14.05< 0.001< 0.001Hemoglobin (g/dL)14.54 ± 1.4112.82 ± 1.4913.3 ± 1.73< 0.0010.024Albumin (g/dL)4.36 ± 0.304.08 ± 0.434.09 ± 0.45< 0.001NSUric acid (mg/dL)5.05 ± 1.457.00 ± 1.306.86 ± 1.57< 0.001NSPhosphate (mg/dL)3.46 ± 0.524.02 ± 0.773.64 ± 0.76< 0.001NSiPTH (pg/mL)53.54 ± 15.34172.26 ± 141.96128.37 ± 110.75< 0.001< 0.00125-hydroxi-vitamin D (ng/mL)20.58 ± 8.3918.13 ± 8.2116.75 ± 7.47< 0.001NSFGF23 (pg/mL)53.97 ± 62.8896.77 ± 78.4497.71 ± 84.06< 0.001NSPotassium (mEq/L)4.47 ± 0.404.71 ± 0.514.75 ± 0.53< 0.001NSProteinuria (g/day)0.07 ± 0.120.32 ± 0.380,98 ± 1.4< 0.0010.04Urine albumin to creatinine ratio (mg/g)34 ± 46214 ± 507427 ± 894< 0.0010.002SBP (mmHg)132.45 ± 17.44140.83 ± 19.56142.99 ± 20.73< 0.001NSDBP (mmHg)79.84 ± 9.6685.14 ± 10.3482.49 ± 10.86< 0.0010.006IMT (mm)0.70 ± 0.120.66 ± 0.110.72 ± 0.14< 0.001< 0.001Pathologic ABI (< 0.9 or > 1.4)62 (12.4%)19 (14.4%)244 (21.8)< 0.0010.027Ischemic ABI (< 0.9)56 (11.4%)14 (11.0%)184 (17.4%)0.0040.041Plaque presence248 (49.7%)71 (53.8%)752 (66.7%)< 0.0010.003Cardiovascular event11 (2.2%)1 (0.8%)73 (6.5%)< 0.0010.008Cardiovascular death0 (0.0%)0 (0.0%)13 (1.2%)0.026NSNon-cardiovascular death3 (0.6%)3 (2.3%)38 (3.4%)0.004NSAbbreviations: ABI ankle brachial index, ADPKD autosomal dominant polycystic kidney disease, BMI body mass index, CKD chronic kidney disease, CKDoe CKD of etiologies other than ADPKD, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate with the CKD-EPI formula, FGF-23 fibroblast growth factor 23, IMT intima-media thickness, iPTH intact parathyroid hormone, NS not statistically significant, SBP systolic blood pressure
Source: ADPKD patients compared to CKDoe patients. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Secondary analysis.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This study is a sub-analysis of the NEFRONA project, which consists of a large prospective multicenter cohort designed to evaluate asymptomatic CVD in patients at different stages of CKD without previous CVE.
Source: Methods.
Finally, a total of 1.751 patients were included: 132 patients with ADPKD were compared with 1121 patients with CKD of other etiologies (CKDoe) and 498 controls (Fig.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
Secondary analysis · BMC Nephrology · 2021
Original publication title
Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls.
Source: BackgroundAbstract: What methods does the paper describe?
We evaluated 2445 CKD patients (2010 to 2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years.
Source: MethodsAbstract: Results
ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221 to 0.808, p = 0.009).
Source: ResultsAbstract: Conclusion
ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD.
Source: ConclusionAuthors’ abstract
Background
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls.
Methods
We evaluated 2445 CKD patients (2010 to 2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years.
Results
ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221 to 0.808, p = 0.009).
Conclusion
ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12882-021-02313-1.
Publication and source details
Original title: Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
José Luis Gorriz; David Arroyo; Luis D’Marco; Roser Torra; Patricia Tomás; María Jesús Puchades; Nayara Panizo; Jonay Pantoja; Marco Montomoli; José Luis Llisterri; Vicente Pallares-Carratalá; José Manuel Valdivielso
BMC Nephrology · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T13:13:11.409143+00:00
DOI: 10.1186/s12882-021-02313-1 · PMC7995703